Lilly's (LLY) SURMOUNT-OSA program, which involved 469 adults with moderate-to-severe OSA and obesity across multiple countries, also reached a key secondary endpoint based on the percentage ...

The Phase 3 trials dubbed Surmount-OSA evaluated Zepbound in adults with moderate-to-severe OSA with the first trial involving patients who were not on positive airway pressure, or PAP ...

SURMOUNT-OSA Study 1 recruited patients with OSA who were not on positive airway pressure (PAP) therapy, in which a mask is worn during sleep that blows air into the lungs and keeps the airway open.

This approval was based on results from the SURMOUNT-OSA phase 3 clinical trials, which evaluated Tirzepatide (10 mg or 15 mg) for the treatment of moderate-to-severe OSA in adults with obesity, with ...

FDA said the benefit of Zepbound "is likely related to body weight reduction." Patients in the SURMOUNT-OSA studies had an average weight loss of around 20% with Zepbound and PAP treatment and ...

Commentary, September 09, 2024 ADA 2024 SURMOUNT-OSA Results: 'Impressive' in Improving Sleep Apnea Drs Akshay Jain and James Kim discuss the benefits of GLP-1 therapy for sleep apnea, as reported ...

This can lead to some large bumps in the road, as ResMed just discovered. On Saturday, Eli Lilly released the results of a highly anticipated clinical trial called SURMOUNT-OSA. The Phase III study ...

Obstructive sleep apnea (OSA)-induced biological changes include intermittent hypoxia, intermittent hypercapnia, intrathoracic pressure changes, sympathetic activation and sleep fragmentation.